Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

Opinion
Video

Panelists discuss how the phase 3 PULSAR and PHOTON trials demonstrated the efficacy of aflibercept 8 mg through a design comparing 12- and 16-week dosing intervals to the aflibercept 2 mg standard 8-week dosing, with primary end points assessing noninferiority in visual acuity maintenance.

Video content above is prompted by the following:

  • Aflibercept 8 mg was evaluated in the PULSAR and PHOTON trials for neovascular age-related macular degeneration and diabetic macular edema. Could you briefly review the design of these trials?
Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
2 experts in this video
3 experts are featured in this series.
Related Content
An image showing the degeneration of neuron cells. Image credit: ©Corona Borealis – stock.adobe.com

Cognition Therapeutics announces publication reviewing potential of zervimesine (CT1812) in dry AMD

Jordana Joy
March 3rd 2025
Article

One in vitro study included in the manuscript was conducted in collaboration with researchers at the University of Southhampton in the United Kingdom

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A doctor in a white coat and a nurse in teal scrubs shake hands. Image credit: ©master1305 – stock.adobe.com

SpaMedica and Vision Express partner for UK training placement programme

Jordana Joy
February 18th 2025
Article

The partnership with the NHS eye patient servicer will help preregistration optometrists access training in community and hospital settings

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A map of Italy with a magnifying glass resting atop it. Image credit: ©sharafmaksumov – stock.adobe.com

Italian study illuminates positive outcomes and common complications of SING IMT implantation

Lynda Charters
February 6th 2025
Article

The implant was tested in eyes of patients with bilateral age-related macular degeneration who underwent cataract surgery

A man wearing Nuance Audio hearing aid glasses speaks to a friend. Image courtesy of EssilorLuxottica

Nuance Audio hearing aid glasses receive concurrent CE Mark and FDA approval

Emily Kaiser Maharjan
February 4th 2025
Article

The hearing aid glasses from EssilorLuxottica received CE marking under the Medical Devices Regulation of the EMA

© 2025 MJH Life Sciences

All rights reserved.